Angela L Ho1, Martin E O'Malley, George A Tomlinson. 1. Department of Medical Imaging, University Health Network and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Abstract
OBJECTIVE: To evaluate the incidence of adverse events with the universal use of iodixanol for computed tomography (CT) and compare it with periods when iohexol was used exclusively. METHODS: Iodixanol was used for CT in 15,142 consecutive patients and compared with 22,044 patients who received iohexol. RESULTS: Adverse events were observed in 116 patients (0.77%) who received iodixanol and in 54 patients (0.25%) who received iohexol (P < 0.001). Immediate and delayed adverse events were seen in 76 and 40 patients (0.50% and 0.26%, respectively) who received iodixanol and in 52 and 2 patients (0.24% and 0.01%, respectively) who received iohexol, respectively (immediate, P = 0.002; delayed, P < 0.001). Adverse events with iodixanol and iohexol were as follows: mild, 89% and 98%; moderate, 10% and 2%; and severe, 1% and 0%, respectively. CONCLUSIONS: Adverse events occurred in less than 1% of patients receiving either contrast agent. However, the incidence of immediate and delayed adverse events was significantly higher with iodixanol than iohexol.
OBJECTIVE: To evaluate the incidence of adverse events with the universal use of iodixanol for computed tomography (CT) and compare it with periods when iohexol was used exclusively. METHODS:Iodixanol was used for CT in 15,142 consecutive patients and compared with 22,044 patients who received iohexol. RESULTS: Adverse events were observed in 116 patients (0.77%) who received iodixanol and in 54 patients (0.25%) who received iohexol (P < 0.001). Immediate and delayed adverse events were seen in 76 and 40 patients (0.50% and 0.26%, respectively) who received iodixanol and in 52 and 2 patients (0.24% and 0.01%, respectively) who received iohexol, respectively (immediate, P = 0.002; delayed, P < 0.001). Adverse events with iodixanol and iohexol were as follows: mild, 89% and 98%; moderate, 10% and 2%; and severe, 1% and 0%, respectively. CONCLUSIONS: Adverse events occurred in less than 1% of patients receiving either contrast agent. However, the incidence of immediate and delayed adverse events was significantly higher with iodixanol than iohexol.